Pay in 4 interest-free payments of $6.11 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
chance to achieve HbA 1c 23 kg/m 2 with irrelevant variation ( 5%) in last three months
The new indication could give Novo Nordisk a boost against rivals in the GLP-1 agonist class, including Eli Lilly, whose dual GIP/GLP-1 agonist Mounjaro (tirzepatide) competes in the diabetes category and is in a phase 3 trial (TREASURE-CKD) looking at a CKD indication in people with obesity, with and without diabetes
Insurance Coverage for Mounjaro (Type 2 Diabetes) In normal cases, insurance plans cover Mounjaro when prescribed for type 2 diabetes
This translates to roughly 0.5 to 2 pounds per week for most patients, though individual results cluster around a slower, steadier pace in months 2 through 6
US$ 27.89
US$ 23.73
US$ 29.18
US$ 24.20
US$ 20.61
US$ 23.21
US$ 27.18
US$ 25.28
